Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Blood test uses cell-free DNA methylation to quantify tumor burden and more
Fusion mutations may drive tumor growth and could be good targets for treatment.
EAI-432 offers a new approach to targeting mutant-EGFR driven non-small-cell lung cancer, say Dana-Farber researchers.
Gift brings the PMC’s total contributions in support of cancer research and treatment within reach of $1B fundraising milestone in 2024
Bioethics researchers at Dana-Farber call on leaders to ensure that AI preserves autonomy of cancer patients and respects human dignity.
Cabometyx improved progression-free survival versus placebo in people with neuroendocrine tumors inside or outside the pancreas.
Researchers sought to understand both neuroendocrine tumors themselves and the surrounding cells in the tumor microenvironment.
AssessYourRisk, developed by Dana-Farber Cancer Institute, uses a simple quiz to assess a users’ risk of breast or ovarian cancer.
An AI–based tool can evaluate photos of kidney tumor samples and may help predict treatment responses, report Dana-Farber researchers.
Other studies focused on bladder cancer, prostate cancer and liquid biopsies.
Each test can be performed with merely half a drop of blood.
Cancer-related outcomes were similar, but patients reported less burden on life and finances with shorter treatment regimen.
Unlike other cancer immunotherapies, the new agent, mezigdomide, can be taken at home as a daily pill.
Adding chemotherapy to Tagrisso was associated with a nearly nine-month delay in disease progression—and more side effects.
Dana-Farber researchers use artificial intelligence to efficiently diagnose muscle wasting in patients with head and neck cancers.
Overall survival was 14.4 months for HR+/HER2- patients who received sacituzumab govitecan versus 11.2 months for those given chemotherapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.